Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
Open Access
- 9 September 2013
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 123 (10), 4410-4422
- https://doi.org/10.1172/JCI69369
Abstract
The activating receptor NK cell group 2 member D (NKG2D) mediates antitumor immunity in experimental animal models. However, whether NKG2D ligands contribute to tumor suppression or progression clinically remains controversial. Here, we have described 2 novel lines of "humanized" bi-transgenic (bi-Tg) mice in which native human NKG2D ligand MHC class I polypeptide-related sequence B (MICB) or the engineered membrane-restricted MICB (MICB.A2) was expressed in the prostate of the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of spontaneous carcinogenesis. Bi-Tg TRAMP/MICB mice exhibited a markedly increased incidence of progressed carcinomas and metastasis, whereas TRAMP/MICB.A2 mice enjoyed long-term tumor-free survival conferred by sustained NKG2D-mediated antitumor immunity. Mechanistically, we found that cancer progression in TRAMP/MICB mice was associated with loss of the peripheral NK cell pool owing to high serum levels of tumor-derived soluble MICB (sMICB). Prostate cancer patients also displayed reduction of peripheral NK cells and high sMIC levels. Our study has not only provided direct evidence in "humanized" mouse models that soluble and membrane-restricted NKG2D ligands pose opposite impacts on cancer progression, but also uncovered a mechanism of sMIC-induced impairment of NK cell antitumor immunity. Our findings suggest that the impact of soluble NKG2D ligands should be considered in NK cell-based cancer immunotherapy and that our unique mouse models should be valuable for therapy optimization.Keywords
This publication has 53 references indexed in Scilit:
- MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasisInternational Journal of Oncology, 2012
- NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational studyBMC Cancer, 2012
- Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and MetalloproteinasesPublished by The American Association of Immunologists ,2010
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for ImmunoeditingClinical Cancer Research, 2009
- An six-amino acid motif in the α3 domain of MICA is the cancer therapeutic target to inhibit sheddingBiochemical and Biophysical Research Communications, 2009
- Obstructing Shedding of the Immunostimulatory MHC Class I Chain–Related Gene B Prevents Tumor FormationClinical Cancer Research, 2009
- Rapid tolerization of virus-activated tumor-specific CD8 + T cells in prostate tumors of TRAMP miceProceedings of the National Academy of Sciences of the United States of America, 2008
- Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis modelGene Therapy, 2008
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2008